@article{oai:redcross.repo.nii.ac.jp:00016529,
 author = {OHKUBO, Tsunemasa and KAITO, Muichi and ANDO, Toshihiro and KATO, Hideaki},
 journal = {高山赤十字病院紀要},
 month = {Mar},
 note = {Although escitalopram (ESC) is no having dopamine (DA) transporter (DAT) inhibitory-action, having dopamine nerve (A10 nerve) stimulus operation by the ESC used basic experiment is reported. We supposed the mechanism that the DA increases and it supposed the mechanism that makes a non-organic pain disappear with ①5-HT reinforcement of the descending pain modulatory system, ②the opioid receptor activation with the descending pain modulatory system, ③negative emotion block from the amygdala and the hippocampus to the nucleus accumbens, ④5-HT1A receptor stimulation from the activation of the amygdala, ⑤DA-phasic activity activation.
 As a result ④ and ⑤ two items were an operation with a main restraint mechanism of a nonorganic-pain. ESC is different from other SSRIs, and we know that ESC make a DA increase at the VTA. We supposed amygdala that a functional depression declined by corticotropin-releasing factor (CRF) is improved with ④ and ③. After DA stimulate by A10 nerve, DA is undergone metabolic change to, and the endogenous opioid peptide (βendorphin) is made.},
 pages = {31--34},
 title = {The supposition of the mechanism of escitalopram makes a dopamine nerve activity rise by inhibiting corticotropinreleasing factor to the non-organic-pain ～A SSRI application is desirable for a non-organic-pain～},
 volume = {43},
 year = {2020}
}